Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.

被引：0

作者：

Kowal, M

Nowak, W

Nowaczynska, A

Dmoszynska, A

Skotnicki, AB

机构：

[1] Jagiellonian Univ, Fac Med, Dept Haematol, Krakow, Poland

[2] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland

来源：

BLOOD | 2005年 / 106卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5048

引用

页码：343B / 344B

页数：2

共 50 条

[21] Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
Elter, T
Borchmann, P
Schulz, H
Reiser, M
Trelle, S
Schnell, R
Jensen, M
Staib, P
Schinköthe, T
Stützer, H
Rech, J
Gramatzki, M
Aulitzky, W
Hasan, I
Josting, A
Hallek, M
Engert, A
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7024 - 7031
[22] Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
Keating, M
Coutré, S
Rai, K
Österborg, A
Faderl, S
Kennedy, B
Kipps, T
Bodey, G
Byrd, JC
Rosen, S
Dearden, C
Dyer, MJS
Hillmen, P
CLINICAL LYMPHOMA, 2004, 4 (04): : 220 - 227
[23] Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia
Reda, Gianluigi
Maura, Francesco
Gritti, Giuseppe
Gregorini, Anna
Binda, Francesca
Guidotti, Francesca
Piciocchi, Alfonso
Visco, Carlo
Rodeghiero, Francesco
Cortelezzi, Agostino
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (09) : 936 - 937
[24] Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
Marotta, G
Bigazzi, C
Lenoci, M
Tozzi, M
Bocchia, M
Lauria, F
HAEMATOLOGICA, 2000, 85 (12) : 1268 - 1270
[25] Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia
Badoux, Xavier C.
Keating, Michael
O'Brien, Susan
Kadia, Tapan
Ferrajoli, Alessandra
Faderl, Stefan
Koller, Charles
Garcia-Manero, Guillermo
Burger, Jan A.
Wierda, William G.
BLOOD, 2009, 114 (22) : 1332 - 1333
[26] FluCam - a new, 4-weekly combination of fludarabine and alemtuzumab for patients with relapsed chronic lymphocytic leukemia.
Elter, T
Bochmann, P
Schulz, H
Reiser, M
Trelle, S
Staib, P
Schinkothe, T
Hallek, M
Engert, A
BLOOD, 2004, 104 (11) : 690A - 690A
[27] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
Montillo, Marco
Tedeschi, Alessandra
Petrizzi, Valeria Belsito
Ricci, Francesca
Crugnola, Monica
Spriano, Mauro
Spedini, Pierangelo
Ilariucci, Fiorella
Uziel, Lilj
Attolico, Immacolata
Vismara, Eleonora
De Blasio, Angelo
Zaccaria, Alfonso
Morra, Enrica
BLOOD, 2011, 118 (15) : 4079 - 4085
[28] Alemtuzumab is effective in patients with advanced, pretreated B-cell chronic lymphocytic leukemia: A nationwide study of routine use in Austria
Fiegl, M
Falkner, A
Hopfinger, G
Brugger, S
Zabernigg, A
Haslbauer, F
Andel, J
Thaler, J
Fridrik, M
Bauer, F
Mian, M
Tatzreiter, G
Zoier, N
Demirtas, D
Postner, G
Auberger, J
Gastl, G
Greil, R
BLOOD, 2005, 106 (11) : 833A - 833A
[29] T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
Kiaii, S
Mozaffari, F
Lundin, J
Rezvany, R
Chudhury, A
Mellstedt, H
Osterborg, A
BLOOD, 2004, 104 (11) : 689A - 689A
[30] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
Montillo, Marco
Tedeschi, Alessandra
Ricci, Francesca
Zaccaria, Alfonso
Crugnola, Monica
Spriano, Mauro
Spedini, PierAngelo
Ilariucci, Fiorella
Uziel, Lilj
Attolico, Immacolata
De Blasio, Angelo
Vismara, Eleonora
Morra, Enrica
Petrizzi, Valeria Belsito
BLOOD, 2010, 116 (21) : 595 - 596

← 1 2 3 4 5 →